Thyroid eye disease (TED) is treated based on whether the condition is actively inflamed or has stabilized. During the active phase, treatment focuses on reducing inflammation with medications. Once the disease quiets down, typically 12 to 18 months after onset, surgical options can address lasting changes like bulging eyes, double vision, or eyelid retraction. The right approach depends on severity, and mild cases may only need supportive care while severe cases can require both medication and surgery.
Active vs. Inactive Disease: Why It Matters
TED progresses through two distinct phases, and your treatment plan hinges on which one you’re in. Doctors assess this using a Clinical Activity Score (CAS), a simple 7-point checklist that evaluates signs of inflammation: spontaneous pain behind the eye, pain when looking up or down, redness of the eyelids, redness of the white of the eye, eyelid swelling, inflammation of the small fleshy bump in the inner corner of the eye, and swelling of the clear membrane covering the white of the eye. A score of 3 or higher signals active disease.
In the active phase, the immune system is attacking the tissues around your eyes, causing swelling, fluid buildup, and fat expansion. Medical treatments during this window aim to shut down that inflammation before it causes permanent damage. In the inactive phase, inflammation has burned out but left behind fibrosis and excess fat tissue. At that point, surgery becomes the primary tool for correcting what the disease left behind.
Steroid Treatment for Moderate to Severe TED
Intravenous steroids are the standard first-line treatment for active TED that’s moderate or severe. The typical protocol involves weekly infusions over 12 weeks, with higher doses in the first six weeks followed by lower doses in the second six. For moderate disease, the starting weekly dose is 500 mg for six weeks, then 250 mg for six weeks. Severe cases use 750 mg followed by 500 mg on the same schedule.
Cumulative doses above 6 to 8 grams carry risks of serious complications including liver failure, stroke, and blood clots in the lungs, so doctors monitor liver function closely throughout treatment. Oral steroids are sometimes used but tend to cause more systemic side effects than the intravenous route and are generally less effective.
Teprotumumab: A Targeted Option
Teprotumumab works differently from steroids. It blocks a specific receptor on the surface of cells behind the eye that drives much of the tissue expansion in TED. In its phase 3 clinical trial, 83% of patients receiving teprotumumab achieved a reduction of 2 mm or more in eye bulging (proptosis) after 24 weeks, compared with just 10% of patients on placebo. The treatment is given as a series of intravenous infusions over about 21 weeks.
Side effects are mostly mild to moderate, but hearing impairment has been reported. In the phase 3 trial, five patients in the treatment group experienced some degree of hearing problems. Other potential concerns include muscle spasms, nausea, and changes in blood sugar. The cost of teprotumumab is significant, and insurance coverage varies, which remains a practical barrier for many patients.
Orbital Radiation
Orbital radiotherapy is sometimes used alongside steroids for active TED, particularly when steroids alone aren’t enough. The standard course delivers 20 Gy split across 10 sessions. Radiation targets the inflammatory immune cells behind the eye and can help reduce swelling and improve eye movement. It’s most effective when combined with steroid therapy rather than used on its own, and the full benefits may take several months to appear.
Mild TED and Supportive Care
Not every case of TED requires aggressive treatment. Mild disease, where symptoms are bothersome but don’t threaten vision or significantly affect daily life, can often be managed with supportive measures. Artificial tears and lubricating gels help with the dryness and irritation that come from eyes that don’t close fully or blink normally. Sleeping with the head elevated can reduce morning swelling. Wearing sunglasses helps with light sensitivity and wind irritation.
Selenium supplementation has shown modest benefit in mild active TED. A randomized controlled trial found that taking 200 micrograms of selenium daily for six months during the active inflammation phase reduced disease severity. Selenium is an inexpensive, low-risk option that’s often recommended alongside other supportive measures for people with mild symptoms.
Why Quitting Smoking Changes Outcomes
Smoking is the single most important modifiable risk factor for TED. A large study of nearly 88,000 adults with Graves’ disease found that current smokers were almost twice as likely to need orbital decompression surgery (3.7%) compared with people who had never smoked (1.9%). The pattern held across other surgeries too: 4.6% of current smokers needed strabismus surgery versus 2.2% of never smokers, and eyelid surgery rates were 4.1% versus 2.6%.
The encouraging finding is that quitting makes a measurable difference. Former smokers had surgery rates much closer to those of never smokers, demonstrating that stopping tobacco use reduces the likelihood of TED progressing to the point where surgery becomes necessary. Smoking also blunts the effectiveness of steroid treatment and orbital radiation, making it harder to control the disease even with appropriate therapy.
Surgery for Lasting Changes
Once TED has been stable for several months, surgery can address the structural changes the disease left behind. There’s a specific sequence that surgeons follow because each procedure can affect the results of the next.
- Orbital decompression comes first. This removes bone or fat from the eye socket to make room, allowing the eyes to settle back into a more normal position. Patients typically pursue this when bulging is severe enough to cause chronic pain, headaches, corneal scarring from exposure, or vision loss from pressure on the optic nerve. The procedure can be done endoscopically (through the nose) or through skin incisions, depending on how much correction is needed.
- Strabismus surgery comes second. Double vision is one of the most disabling symptoms of TED, caused by scarring and stiffness in the muscles that move the eyes. Before surgery is considered, the degree of misalignment and thyroid function both need to be stable. In the meantime, prism lenses added to glasses can help compensate for the misalignment, either as a temporary bridge or as a long-term solution for small angles of double vision.
- Eyelid surgery comes last. This corrects retraction (where the upper or lower lid pulls back, showing too much white of the eye) and addresses any excess tissue. It’s done after decompression and strabismus correction because both of those procedures can change eyelid position.
In some cases, patients with severely debilitating double vision or extreme head tilting to compensate for misalignment may undergo strabismus surgery earlier than the standard sequence would suggest. But for most people, waiting until the disease is fully quiet produces more predictable, lasting results.
Thyroid Control and TED
Managing TED effectively also means keeping thyroid hormone levels stable. Both overactive and underactive thyroid states can worsen eye disease, so the goal is to reach and maintain normal thyroid function as quickly as possible. This is especially important after radioactive iodine treatment for Graves’ disease, which can temporarily worsen TED if thyroid levels swing before stabilizing. Close coordination between your endocrinologist and eye specialist helps ensure that thyroid treatment decisions account for the status of your eye disease.